New combo therapy aims to stop liver cancer from coming back after surgery

NCT ID NCT07522411

Not yet recruiting Disease control Sponsor: BinYong Liang Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving a mix of chemotherapy, immunotherapy, and targeted therapy before surgery can reduce the risk of liver cancer returning in patients with high-risk features. About 100 participants will either receive the combination treatment followed by surgery, or surgery alone. The goal is to see if the pre-surgery treatment improves cancer-free survival at two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sintilimab, bevacizumab, FOLFOX chemotherapy, and transarterial chemoembolization (TACE)
What this could lead to: If successful, this approach could lower the chance of liver cancer returning after surgery and improve long-term survival for high-risk patients.
What could go wrong: This is an early-phase study with only 100 participants, so results may not apply broadly. The combination therapy has significant side effects, including bleeding and immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.